Logo image of CDXS

CODEXIS INC (CDXS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CDXS - US1920051067 - Common Stock

1.67 USD
-0.11 (-6.18%)
Last: 1/16/2026, 8:00:02 PM
1.67 USD
0 (0%)
After Hours: 1/16/2026, 8:00:02 PM
Fundamental Rating

2

CDXS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of CDXS have multiple concerns. CDXS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year CDXS has reported negative net income.
  • CDXS had a negative operating cash flow in the past year.
  • In the past 5 years CDXS always reported negative net income.
  • In the past 5 years CDXS reported 4 times negative operating cash flow.
CDXS Yearly Net Income VS EBIT VS OCF VS FCFCDXS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

  • CDXS's Return On Assets of -51.59% is on the low side compared to the rest of the industry. CDXS is outperformed by 84.21% of its industry peers.
  • With a Return On Equity value of -165.92%, CDXS is not doing good in the industry: 82.46% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -51.59%
ROE -165.92%
ROIC N/A
ROA(3y)-37.68%
ROA(5y)-26.51%
ROE(3y)-69.59%
ROE(5y)-47.16%
ROIC(3y)N/A
ROIC(5y)N/A
CDXS Yearly ROA, ROE, ROICCDXS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • CDXS has a better Gross Margin (79.31%) than 98.25% of its industry peers.
  • In the last couple of years the Gross Margin of CDXS has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for CDXS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 79.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.68%
GM growth 5Y-1.2%
CDXS Yearly Profit, Operating, Gross MarginsCDXS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

3

2. Health

2.1 Basic Checks

  • CDXS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CDXS has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for CDXS has been increased compared to 5 years ago.
  • CDXS has a worse debt/assets ratio than last year.
CDXS Yearly Shares OutstandingCDXS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CDXS Yearly Total Debt VS Total AssetsCDXS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -6.50, we must say that CDXS is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of CDXS (-6.50) is worse than 87.72% of its industry peers.
  • A Debt/Equity ratio of 1.03 is on the high side and indicates that CDXS has dependencies on debt financing.
  • The Debt to Equity ratio of CDXS (1.03) is worse than 80.70% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.03
Debt/FCF N/A
Altman-Z -6.5
ROIC/WACCN/A
WACC11.79%
CDXS Yearly LT Debt VS Equity VS FCFCDXS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 4.12 indicates that CDXS has no problem at all paying its short term obligations.
  • CDXS has a better Current ratio (4.12) than 63.16% of its industry peers.
  • A Quick Ratio of 4.02 indicates that CDXS has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 4.02, CDXS is in the better half of the industry, outperforming 70.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.12
Quick Ratio 4.02
CDXS Yearly Current Assets VS Current LiabilitesCDXS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 12.64% over the past year.
  • The Revenue for CDXS has decreased by -17.87% in the past year. This is quite bad
  • The Revenue has been decreasing by -2.83% on average over the past years.
EPS 1Y (TTM)12.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.14%
Revenue 1Y (TTM)-17.87%
Revenue growth 3Y-17.27%
Revenue growth 5Y-2.83%
Sales Q2Q%-32.98%

3.2 Future

  • CDXS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.71% yearly.
  • Based on estimates for the next years, CDXS will show a quite strong growth in Revenue. The Revenue will grow by 19.17% on average per year.
EPS Next Y25.65%
EPS Next 2Y24.37%
EPS Next 3Y21.3%
EPS Next 5Y12.71%
Revenue Next Year3.05%
Revenue Next 2Y4.13%
Revenue Next 3Y13.34%
Revenue Next 5Y19.17%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CDXS Yearly Revenue VS EstimatesCDXS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M 500M
CDXS Yearly EPS VS EstimatesCDXS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 0.5 -0.5 1 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CDXS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CDXS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CDXS Price Earnings VS Forward Price EarningsCDXS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CDXS Per share dataCDXS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

  • CDXS's earnings are expected to grow with 21.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.37%
EPS Next 3Y21.3%

More info and screens

0

5. Dividend

5.1 Amount

  • CDXS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CODEXIS INC

NASDAQ:CDXS (1/16/2026, 8:00:02 PM)

After market: 1.67 0 (0%)

1.67

-0.11 (-6.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-06
Earnings (Next)02-25
Inst Owners70.6%
Inst Owner Change6.11%
Ins Owners2.46%
Ins Owner Change2.34%
Market Cap150.83M
Revenue(TTM)52.93M
Net Income(TTM)-63.95M
Analysts81.54
Price Target6.71 (301.8%)
Short Float %6.63%
Short Ratio5.11
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-14.18%
Min EPS beat(2)-45.17%
Max EPS beat(2)16.81%
EPS beat(4)1
Avg EPS beat(4)-70.83%
Min EPS beat(4)-251.59%
Max EPS beat(4)16.81%
EPS beat(8)3
Avg EPS beat(8)-35.92%
EPS beat(12)5
Avg EPS beat(12)-23.74%
EPS beat(16)9
Avg EPS beat(16)-8.31%
Revenue beat(2)1
Avg Revenue beat(2)-23.96%
Min Revenue beat(2)-54.44%
Max Revenue beat(2)6.53%
Revenue beat(4)1
Avg Revenue beat(4)-23.66%
Min Revenue beat(4)-54.44%
Max Revenue beat(4)6.53%
Revenue beat(8)4
Avg Revenue beat(8)-3.25%
Revenue beat(12)5
Avg Revenue beat(12)-3.57%
Revenue beat(16)8
Avg Revenue beat(16)-0.26%
PT rev (1m)0%
PT rev (3m)-1.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)61.32%
EPS NY rev (1m)0%
EPS NY rev (3m)0.17%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)47.5%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.45%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.85
P/FCF N/A
P/OCF N/A
P/B 3.91
P/tB 4.18
EV/EBITDA N/A
EPS(TTM)-0.76
EYN/A
EPS(NY)-0.41
Fwd EYN/A
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0.59
BVpS0.43
TBVpS0.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -51.59%
ROE -165.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 79.32%
FCFM N/A
ROA(3y)-37.68%
ROA(5y)-26.51%
ROE(3y)-69.59%
ROE(5y)-47.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.68%
GM growth 5Y-1.2%
F-Score3
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 1.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 209.25%
Cap/Sales 10.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.12
Quick Ratio 4.02
Altman-Z -6.5
F-Score3
WACC11.79%
ROIC/WACCN/A
Cap/Depr(3y)106.81%
Cap/Depr(5y)185.7%
Cap/Sales(3y)6.52%
Cap/Sales(5y)7.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.14%
EPS Next Y25.65%
EPS Next 2Y24.37%
EPS Next 3Y21.3%
EPS Next 5Y12.71%
Revenue 1Y (TTM)-17.87%
Revenue growth 3Y-17.27%
Revenue growth 5Y-2.83%
Sales Q2Q%-32.98%
Revenue Next Year3.05%
Revenue Next 2Y4.13%
Revenue Next 3Y13.34%
Revenue Next 5Y19.17%
EBIT growth 1Y-17.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.2%
EBIT Next 3Y12.55%
EBIT Next 5Y12.02%
FCF growth 1Y-48.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-52.46%
OCF growth 3YN/A
OCF growth 5YN/A

CODEXIS INC / CDXS FAQ

Can you provide the ChartMill fundamental rating for CODEXIS INC?

ChartMill assigns a fundamental rating of 2 / 10 to CDXS.


What is the valuation status for CDXS stock?

ChartMill assigns a valuation rating of 1 / 10 to CODEXIS INC (CDXS). This can be considered as Overvalued.


Can you provide the profitability details for CODEXIS INC?

CODEXIS INC (CDXS) has a profitability rating of 1 / 10.


Can you provide the financial health for CDXS stock?

The financial health rating of CODEXIS INC (CDXS) is 3 / 10.


Can you provide the expected EPS growth for CDXS stock?

The Earnings per Share (EPS) of CODEXIS INC (CDXS) is expected to grow by 25.65% in the next year.